FibroGen (NASDAQ:FGEN) Releases Earnings Results, Beats Estimates By $0.06 EPS

FibroGen (NASDAQ:FGEN) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports.

FibroGen Stock Performance

FGEN traded up $0.01 during trading on Monday, hitting $0.45. The stock had a trading volume of 1,363,100 shares, compared to its average volume of 2,320,345. The company has a market capitalization of $44.84 million, a PE ratio of -0.36 and a beta of 0.82. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80. The stock has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $0.43.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on FGEN. StockNews.com began coverage on shares of FibroGen in a research note on Friday. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research note on Thursday, February 20th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.